Stereotaxis, CardioFocus collaborate to advance robotic PFA technology

Stereotaxis (STXS) and CardioFocus announced they have entered into a Collaboration Agreement to advance robotic Pulsed Field Ablation, PFA, technology towards commercialization. The collaboration combines the proprietary technologies of both companies to accelerate commercial availability of the first-ever robotic PFA solution for the treatment of cardiac arrhythmias. “We are excited to collaborate with CardioFocus to accelerate bringing robotic PFA to the Electrophysiology community,” said David Fischel, Stereotaxis Chairman and CEO. “The precision, stability and safety profile of robotics with the efficiency and attractive lesions created by Centauri is a winning combination. We look forward to transitioning to first human use and advancing the regulatory process in the coming few months.”